A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant
Latest Information Update: 18 Jan 2024
At a glance
- Drugs Lutetium-177 lilotomab satetraxetan (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Acronyms LYMRIT-37-05
- Sponsors Nordic Nanovector
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 10 Jun 2022 According to a Nordic Nanovector media release, latest data from this trial will be presented at the European Hematology Association (EHA) Congress 2022.
- 10 Jun 2022 Results published in the Nordic Nanovector Media Release.